儿童单纯疱疹脑炎后抗 NMDAR 脑炎二线治疗用利妥昔单抗。
Rituximab as Second-Line Treatment in Anti-NMDAR Encephalitis after Herpes Simplex Encephalitis in Children.
机构信息
Department of Pediatrics, Pediatric Infectious Diseases Unit, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), RITIP, Madrid, Spain.
Department of Pediatrics, Pediatric Intensive Care Unit, Hospital Universitario, 12 de Octubre, Madrid, Spain.
出版信息
Indian J Pediatr. 2022 Oct;89(10):1031-1033. doi: 10.1007/s12098-022-04170-8. Epub 2022 Apr 25.
The long-term response of two infants with anti-N-methyl-D-aspartate receptor (anti-NMDAR) post herpes simplex encephalitis treated with rituximab is reported here. Rituximab may improve the course of the disease and should be considered early as second-line treatment. Data on the long-term effect of rituximab in B cell depletion and immunoglobulins levels in infants are needed.
现报道 2 例抗 N-甲基-D-天冬氨酸受体（anti-NMDAR）抗体阳性疱疹性脑炎婴儿应用利妥昔单抗治疗的长期疗效。利妥昔单抗可能改善疾病进程，应作为二线治疗尽早应用。目前尚缺乏利妥昔单抗在婴幼儿 B 细胞耗竭和免疫球蛋白水平方面长期作用的数据。
Zotero 插件